...acquired Innodia for C$1.3 million (US$1.3 million) in stock. The purchase includes the assumption of Innodia's...
...II diabetes, with interim data expected in 1H09. Bellus Health Inc. (TSX:BLU; NASDAQ:BLUS), Laval, Quebec Innodia Inc....

...blocks NPY5 receptor (4) . The mechanisms for Manhattan Pharmaceuticals' natural hormone oleoyl-esterone and Innodia's...

...up the body's energy expenditure without a concomitant increase in appetite. In that camp is Innodia Inc....
...of fat into triglycerides. While Adyvia was initially developed for Type II diabetes, Vezeau said Innodia...
...and lipid profile. While the exact mechanism of Adyvia has yet to be fully elucidated, Innodia...

...data 07 (A) GlaxoSmithKline/ Kissei Sergliflozin (869682, KGT-1251) Sodium-glucose cotransporter 2 (SGLT2) inhibitor SGLT2 NA Innodia...

...Innodia began a double-blind, placebo-controlled, Canadian Phase IIa trial in 100 patients. Innodia Inc. , Laval, Quebec...

...Diabetes and obesity company Innodia (Laval, Quebec) hired Nigel Levens as CSO, a newly created position...

...In a slight twist on the typical NRDO business model, Innodia Inc. has no internal research capabilities...
...targets that will allow the company to "broaden the way in which diabetes is attacked." Innodia's...
...that Innodia's strategy is to partner or out-license each of its programs after Phase IIb. Innodia...